As previously reported, Benchmark analyst Bruce Jackson initiated coverage of Abbott (ABT) with a Buy rating and $145 price target Abbott’s diversified business model, which does not rely on a single therapy, technology, or geography, gives it “a resilient foundation” for sustainable mid-single digit sales growth and double-digit adjusted EPS growth, the analyst tells investors. Exposure to multiple high-demand healthcare sectors and an expanding international business can help the company “mitigate an uncertain macro climate,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott Laboratories: Diversified Growth and Strategic Investments Justify Buy Rating
- Abbott initiated with a Buy at Benchmark
- Looking for Exposure to UnitedHealth Stock (UNH)? Here’s How to Buy Without the Risk
- Abbott added to US Conviction List at Goldman Sachs
- DexCom assumed with Perform from Outperform at Oppenheimer